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Neurotrophic factors (NTFs) are small secreted proteins that support the development,
maturation and survival of neurons. NTFs injected into the brain rescue and regenerate
certain neuronal populations lost in neurodegenerative diseases, demonstrating the
potential of NTFs to cure the diseases rather than simply alleviating the symptoms.
NTFs (as the vast majority of molecules) do not pass through the blood–brain barrier
(BBB) and therefore, are delivered directly into the brain of patients using costly and
risky intracranial surgery. The delivery efficacy and poor diffusion of some NTFs inside
the brain are considered the major problems behind their modest effects in clinical
trials. Thus, there is a great need for NTFs to be delivered systemically thereby avoiding
intracranial surgery. Nanoparticles (NPs), particles with the size dimensions of 1-100 nm,
can be used to stabilize NTFs and facilitate their transport through the BBB. Several
studies have shown that NTFs can be loaded into or attached onto NPs, administered
systemically and transported to the brain. To improve the NP-mediated NTF delivery
through the BBB, the surface of NPs can be functionalized with specific ligands such
as transferrin, insulin, lactoferrin, apolipoproteins, antibodies or short peptides that will
be recognized and internalized by the respective receptors on brain endothelial cells.
In this review, we elaborate on the most suitable NTF delivery methods and envision
“ideal” NTF for Parkinson’s disease (PD) and clinical trial thereof. We shortly summarize
clinical trials of four NTFs, glial cell line-derived neurotrophic factor (GDNF), neurturin
(NRTN), platelet-derived growth factor (PDGF-BB), and cerebral dopamine neurotrophic
factor (CDNF), that were tested in PD patients, focusing mainly on GDNF and CDNF. We
summarize current possibilities of NP-mediated delivery of NTFs to the brain and discuss
whether NPs have impact in improving the properties of NTFs and delivery across the
BBB. Emerging delivery approaches and future directions of NTF-based nanomedicine
are also discussed.
Keywords: Parkinson’s disease, brain-derived neurotrophic factor, cerebral dopamine neurotrophic factor,
dopamine neurons, endoplasmic reticulum stress, glial cell line-derived neurotrophic factor, nanomedicine,
neuroinflammation
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INTRODUCTION
Potential of Neurotrophic Factors in
Neurodegenerative Diseases and Open
Challenges
Neurotrophic factors (NTFs) (trophic = survival) are typically
proteins of 10 to 35 kDa in molecular weight that support
the development, differentiation, survival and plasticity of
neurons (Huttunen and Saarma, 2019). NTF-based therapies
hold great promise for curing neurodegenerative diseases such as
Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic
lateral sclerosis (ALS), and Huntington’s disease (HD) that are
currently incurable. Compared to potential alternative therapies,
NTFs have the following advantages:
(a) NTFs are disease-modifying. All commercial and most
of the emerging therapeutic approaches alleviate the
symptoms of neurodegenerative diseases without
curing them, while NTFs are able to slow down
neurodegeneration and reverse the diseases at least in
certain animal models and in some clinical trials (Lu et al.,
2013; Chmielarz and Saarma, 2020).
(b) Decrease of NTF levels or knockdown of their receptors
results in neuronal loss and other disease-related outcomes.
Decreased levels of NTFs have been found in the brains of
AD, HD, and PD patients (Rinne et al., 1989; Lorigados
Pedre et al., 2002), while supplementation of NTFs
can protect affected neurons in the animal models of
neurodegenerative diseases. In mice deficient in NTFs or
their receptors disease-related neurons are often lost or
affected (Kramer et al., 2007; Lindahl et al., 2020).
(c) NTFs regulate the functional activity of neurons. This is
achieved by regeneration of neuronal axons, stabilization
and stimulation of synapses and regulation of the synthesis
and release of neurotransmitters and expression of their
transporters (Kumar et al., 2015; Castrén and Antila, 2017).
Despite the mentioned advantages that most of other potential
therapies do not have, early studies have pointed out several
problems associated with the clinical implementation of NTFs.
Two of the most important obstacles observed are the side
effects of NTFs and their low clinical benefit, whereas the
main proposed reason for both is inadequate dosing and
delivery of NTFs into the brain. The very first studies employed
systemic administration of NTFs (Bartus and Johnson, 2017).
However, most of the NTFs have short in vivo half-lives,
poor pharmacokinetic properties and very low penetration rates
through the blood–brain barrier (BBB). Thus, their access to the
neuronal targets is restricted by their proteolytic degradation,
different clearance mechanisms (such as rapid excretion by
kidneys) and binding by various components of peripheral tissues
(Thorne and Frey, 2001).
As the result, NTFs are currently delivered directly into the
brain of PD patients using costly and risky intracranial surgery
(Huttunen and Saarma, 2019). Only mid- and late-stage patients
can be treated using brain surgery, since invasive treatments are
considered unethical for the early stage patients. There is a great
need for the efficient NTF peripheral delivery systems that could
avoid intracranial surgery and allow treating early stage patients.
Current review focuses on the potential of nanoparticle
(NPs)-based strategies to improve the stability and delivery
of NTFs into the brain. We focus mainly on the delivery of
NTFs in PD, and cover well-known NTFs as well as a new
family of unconventional NTFs consisting of mesencephalic
astrocyte-derived neurotrophic factor (MANF) and cerebral
dopamine neurotrophic factor (CDNF) that have recently shown
considerable therapeutic potential in the animal models of PD.
Clinical Potential of NTFs in Parkinson’s
Disease
Parkinson’s disease is the second most common
neurodegenerative disease that affects over 10 million people
throughout the world. PD is characterized by progressive loss
of nigrostriatal dopaminergic neurons in the midbrain that
leads to severe movement disorders (Figure 1) and loss of
peripheral dopaminergic neurons that mediates non-motor
symptoms. Current PD treatment strategies are mostly based on
dopamine replacement medicines and deep brain stimulation
that temporarily alleviate the symptoms. However, none of
the available treatments provide long-lasting relief from the
symptoms and do not slow down or stop neurodegeneration.
The use of NTFs as the disease-modifying treatment in PD has
been explored for around 20 years, whereas several NTFs have
shown a considerable potential (Table 1).
Nerve growth factor (NGF) was the first NTF used in PD
patients, and it was tested in one PD patient as support for
the adrenal chromaffin tissue graft in the putamen (Olson
et al., 1991). In the above-mentioned study, intraputamenal
infusion of NGF was applied and resulted in the prolonged
functional improvement compared to the earlier studies using
the grafts without the support of NGF. However, later studies
using the intraventricular infusion of NGF in AD patients
concluded that the “negative side effects appear to outweigh
the positive effects” (Jönhagen et al., 1998), at least for the
intraventricular route of administration, and the clinical trials
with NGF in PD patients were not conducted. In addition,
dopamine neurons do not express a transmembrane receptor
tyrosine-kinase (TrkA), a high-affinity receptor of NGF, and
do not respond to NGF (Holtzman et al., 1995). In addition
to NGF that was tested in one patient, four growth factors,
glial cell line-derived neurotrophic factor (GDNF), neurturin
(NRTN), platelet-derived growth factor (PDGF-BB), and CDNF
have been tested in clinical trials in PD patients. The results
of the clinical studies with GDNF, NRTN, and PDGF-BB
were summarized by Sullivan and Toulouse (2011), recently
updated by Huttunen and Saarma (2019), Barker et al. (2020),
and Sidorova and Saarma (2020) and briefly summarized in
Table 1. The clinical benefit of NTFs in these clinical trials
was mostly assessed using Unified Parkinson’s Disease Rating
Scale (UPDRS) demonstrating the severity of motor symptoms.
Additionally, most of the studies evaluated the activity of
dopamine transporters (DAT) using DAT positron emission
tomography (DAT PET) as an indirect method for assessing the
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FIGURE 1 | Schematic midsagittal cross-section of the human brain. Dopaminergic neurons localize in substantia nigra pars compacta and project their axons into
striatum. In clinical trials with PD patients NTFs were delivered intracranially into lateral ventricles (glial cell line-derived neurotrophic factor, GDNF) or, predominantly,
into putamen [GDNF, neurturin (NRTN), platelet-derived growth factor (PDGF-BB) and cerebral dopamine neurotrophic factor (CDNF)].
severity of the degradation of nigrostriatal dopamine neurons.
While some of the studies demonstrated beneficial effects of
NTFs, especially on DAT activity level, the others concluded




The first NTF discovered (Levi-Montalcini and Hamburger,
1951). NGF was tested in one PD patient as a supporting





Most studied NTF in PD. GDNF was discovered by Lin et al.
(1993). In 1994 the first in vivo study with GDNF
demonstrated that intranigrally injected GDNF improved
apomorphine-induced rotational behavior in
6-hydroxydopamine (6-OHDA)-injected rats (Hoffer et al.,
1994). Six clinical trials were conducted with GDNF (Gill
et al., 2003; Nutt et al., 2003; Slevin et al., 2005; Lang
et al., 2006; Heiss et al., 2019; Whone et al., 2019). In
these trials, GDNF was injected into the brain in the form of
protein or in the form of gene therapy with viral vector.
Neurturin (NRTN) NRTN demonstrated neurorestorative properties in the
nigrostriatal neurons in animal models of PD (Kotzbauer
et al., 1996). Intraputaminal adeno-associated type-2 viral
vector (AAV2)–delivered gene of NRTN was not superior to
sham surgery when assessed using the UPDRS motor





PDGF-BB demonstrated neurorestorative properties in the
nigrostriatal neurons in animal models of PD (Zachrisson
et al., 2011). No change in clinical rating scores in





CDNF was discovered in 2007 and demonstrated
neurorestorative properties in the nigrostriatal neurons in
animal models (Lindholm et al., 2007). CDNF achieved its
primary endpoint of safety and tolerability in a recent phase
I-II clinical trial (Herantis Pharma, 2020; ClinicalTrials.gov:
NCT03295786, NCT03775538).
a lack of the benefit. We discuss possible reasons of this
discrepancy below.
Glial cell line-derived neurotrophic factor is the most studied
NTF in PD. GDNF acts on neurons through its receptor,
tyrosine kinase rearranged during transfection (RET) in the
presence of a co-receptor, GDNF Family Receptor α1 (GFRα1)
(Figure 2). RET activation triggers complex intracellular
signaling cascades, promoting the survival and regeneration of
neurons (Airaksinen and Saarma, 2002).
Six clinical trials in PD patients with GDNF were conducted.
Two open-label trials demonstrated the improvement in
UPDRS (Gill et al., 2003; Slevin et al., 2005), whereas one
open-label and two double-blind placebo controlled clinical
trials resulted in no improvement in UPDRS (Nutt et al.,
2003; Lang et al., 2006; Whone et al., 2019). One gene
therapy approach using an AAV2 vector to deliver GDNF
gene to putamen of PD patients with some encouraging
preliminary results is still ongoing: NCT01621581 (Heiss
et al., 2019). Possible reasons of conflicting results from
different clinical trials with GDNF can be attributed to
several factors: delivery site of GDNF in the brain (putamen
vs. cerebral ventricles), origin of the NTF (mammalian vs.
bacterial), development of anti-NTF antibodies, different NTF
dosage/delivery regimens, and differences in the age of the
patients and stages of the disease. Below we briefly comment on
the studies, where GDNF did not show improvement in UPDRS
compared to placebo.
In the first clinical trial, GDNF was delivered into lateral
ventricle (Nutt et al., 2003). It is currently suggested that
GDNF did not reach nigral neurons using this delivery method.
In the study by Lang et al. (2006), development of anti-
GDNF antibodies in the blood of PD patients was observed,
suggesting the leakage of GDNF into periphery and, as a result,
its insufficient delivery of NTF to the brain that might have
compromised the results. Indeed, only less than 10% total
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FIGURE 2 | Schematic structure of two neurotrophic factors, GDNF and CDNF, and their modes of action in neurons. GDNF signals through receptor tyrosine kinase
RET in the presence of a GDNF binding co-receptor, GFRα1. Upon activation, RET is transphosphorylated at cytoplasmic tyrosine residues and triggers complex
intracellular signaling cascades, Akt, MAPK, and c-Src signaling pathways, promoting the survival and regeneration of neurons (modified from Airaksinen and
Saarma, 2002). CDNF receptors are not identifyed yet. Presumably, CDNF signals through the receptor localized on the endoplasmatic reticulum membrane,
alleviating unfolded protein response, reducing inflammation and promoting the survival of neurons.
putaminal coverage by GDNF was observed in this clinical trial,
suggesting insufficient delivery (Salvatore et al., 2006). In the
study by Whone et al. (2019), during a course of 40 weeks,
intermittent GDNF intraputamenal infusions (120 µg GDNF
to each putamen) were performed once every 4 weeks. The
cumulative 4-week GDNF dose per putamen in this study was
3.5-fold smaller than in the continuous dosing study by Lang
et al. (2006) (120 µg vs. 420 µg). The resulting tissue GDNF
concentrations in the exposed volumes were estimated to be∼18-
fold lower in the study by Whone et al. (2019), suggesting that
delivered GDNF dose was insufficient. Altogether, three clinical
trials, where GDNF did not demonstrate improvement in UPDRS
compared to placebo, had considerable drawbacks in the study
design that have been widely discussed. In addition, all these
studies used GDNF produced in Escherichia coli that rendered
unglycosylated GDNF. GDNF has seven S-S-bridges that are not
formed in E. coli. For these reasons bacterially produced GDNF
was shown to possess a lower stability and activity than the GDNF
produced in mammalian cells (Piccinini et al., 2013, Grondin
et al., 2019).
Cerebral dopamine neurotrophic factor and MANF are the
newest discovered NTFs with unconventional structure and
modes of actions (Lindahl et al., 2017; Figure 2). CDNF was
discovered in 2007 and showed a greater potential to cure PD
in vivo compared to the “gold standard” NTF–GDNF (Lindholm
et al., 2007; Voutilainen et al., 2011). A first-in-man clinical study
with intraputamenal CDNF, a Phase I-II randomized, placebo-
controlled, double-blind, multicenter clinical study in patients
with advanced PD (>10 years since first motor symptoms) was
conducted by Herantis Pharma Plc. and was completed in August
2020 (manuscript in preparation). CDNF was administered
into the putamen of the patients once a month for 6 months
at either mid-dose (120 µg for 2 months and 400 µg for
the following 4 months) or high-dose (120 µg for 2 months,
400 µg for 2 months and 1200 µg for 2 months), followed
by a 6-month active treatment extension study, in which all
patients received one of two doses of CDNF, including the
placebo group. CDNF achieved its primary endpoint of safety
and tolerability. In addition to the primary safety endpoint,
secondary endpoints assessing e.g., severity of motor symptoms
by UPDRS, and exploratory assessments evaluating the integrity
of nigrostriatal dopaminergic system by DAT PET, actigraphy
and cerebrospinal fluid proteomics were included. Significant
increases in DAT PET signaling and improved UPDRS scores
were observed in some but not all CDNF-treated patients. Further
clinical studies with non-invasive CDNF delivery are planned
(Herantis Pharma, 2020).
As mentioned, a sub-group of patients in the clinical study
with CDNF and all GDNF-treated patients in a study with GDNF
conducted by Whone et al. (2019) had a significant increase in
DAT PET signaling, but only some of the patients had improved
UPDRS score: a post hoc analysis found nine (43%) patients in
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the GDNF-treated group but no placebo patients with a large
clinically important motor improvement (≥10 points) in the OFF
state. Whone et al. (2019) thoroughly discussed possible reasons
for the phenomenon and asked whether patient phenotypes had
played a role. However, post hoc covariate analyses investigating
phenotypic characteristics such as age, disease duration, disease
severity, and tremor predominance did not identify any subtype
of the patients who experienced an enhanced benefit (Whone
et al., 2019). It would be tempting to identify a subgroup of
PD patients that are either more or less likely to respond to
GDNF/CDNF therapy.
Together with CDNF, MANF belongs to a novel evolutionarily
conserved family of NTFs. MANF was discovered in 2003 and
was shown to selectively protect nigral dopamine neurons in vitro
(Petrova et al., 2003) and in vivo in animal models (Voutilainen
et al., 2009). Despite that MANF was discovered earlier than
CDNF, it has not yet been tested in clinical trials. The potency
of MANF to protect dopamine neurons in vivo in a rat PD model
(unilateral intrastriatal injection of 6-OHDA) was shown to be
lower compared to CDNF. While MANF demonstrated potential
to rescue cell bodies of dopamine neurons in the substantia
nigra (SN) pars compacta (SNpc) in a 6-OHDA rat model, its
protective effect on neuronal axons (the fibers of dopamine
neurons in the striatum) was modest or absent (Voutilainen
et al., 2009, 2011), making it a dubious NTF candidate for
clinical trials in PD patients. However, the fact that MANF
mitigates the inflammatory response and ER stress warrants
further studies of neurorestorative potential of this NTF in other
neurodegenerative diseases (Kovaleva et al., 2020; Yagi et al.,
2020).
DISCUSSION
Ideal NTF and Hypothetical Perfectly
Designed Clinical Trial
Clinical studies with NTFs have vastly advanced our
understanding of the proteins that should be taken into
account for the design of clinical trials with NTFs in PD patients.
Some of the design parameters are shown in Box 1.
Delivery Method–Systemic vs. Intracranial
Systemic (non-invasive) administration of NTFs would be the
ideal method of delivery. Although early research articles
demonstrated some benefits of NTFs delivered systemically,
BOX 1 | Properties of the ideal NTF for PD.
1. Can be delivered systemically (e.g., intranasal or injection enabling to avoid
brain surgery);
2. Good diffusion in the brain enabling to reach target cells;
3. Stability in the body fluids (e.g., blood) and tissues enabling to reach
the target cells in sufficient concentrations;
4. Specificity toward dopamine neurons enabling reduction of side effects;
5. Ability to treat non-motor symptoms;
6. Systemic delivery without side effects and immune response;
7. Possibility of starting treatment soon after diagnosis when significant
number of dopamine neurons are still alive.
later better controlled studies failed to replicate the efficiency
or identified serious side effects of NTFs that limited the
dosage (Bartus and Johnson, 2017). These disappointing results
promoted the implementation of the invasive methods, where
NTFs were delivered directly into the brain, eihter by infusion
of the protein using mini-pumps or gene delivery with viral
vectors. There are several serious problems associated with
the intracranial delivery. Firstly, intracranial delivery implies a
costly and risky neurosurgical procedures associated with safety
concerns that may result in different adverse outcomes such as
inflammation (Lang et al., 2006). Secondly, development of anti-
NTF antibodies may occur, if NTF leaks into the periphery.
Previous study suggested that anti-GDNF antibodies developed
due to the leakage of intra-putaminally infused GDNF into the
periphery (Barker et al., 2020). Thirdly, intracranial delivery of
NTFs does not allow treatment of many non-motor symptoms
of PD. Finally, due to the ethical considerations and severity
of microsurgical intervention, only middle to late-stage patients
are eligble for the intracranial treatment with NTFs that poses
a problem for efficacy of NTFs: the more advanced is PD, the
less DA neurons are in the brain to protect leading to decreased
efficiency of the therapy.
Delivery Site, Dosing Device and Diffusion Inside the
Brain
Degeneration of dopamine neurons starts from their synapses
and the axons in caudate putamen (Figure 1), whereas cell
bodies in the SNpc degenerate later. NTFs are not able to reverse
the apoptosis of completely degenerated neurons; instead, they
restore the axons of the stressed and degenerating dopamine
neurons and their contacts (Sidorova and Saarma, 2020). Thus,
the degenerating axons in caudate putamen are the main targets
of NTFs, and according to current understanding, the NTFs
should be delivered to the axons of the neurons into caudate
putamen (discussed in more details below).
There are mainly two methods to deliver NTFs directly into
the brain:
(1) The intracerebroventricular method that relies on the
implantation of a catheter and or an internal reservoir with
the drug followed by controlled drug injection from this
reservoir into lateral ventricle.
(2) The intraparenchymal/intracerebral method relying
on the placement of tiny catheters into the brain
parenchyma and continuous or periodical connection of
the catheters to the external drug reservoir. Drug either
diffuses inside the brain by a concentration gradient
(“regular” injection) or “pumped” using a positive pressure
gradient pump [convection enhanced delivery (CED)]
(Furtado et al., 2018).
In the first attempt to treat human PD patients with GDNF,
the intracerebroventricular delivery method was applied and
resulted in no improvement in the UPDRS (Nutt et al., 2003).
Since GDNF diffuses poorly in the brain, it was hypothesized
that GDNF never reached the nigral target neurons in sufficient
quantities. Since the pool of cerebrospinal fluid in the brain
ventricles is turned over every 4–5 h and any drug injected
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into the ventricles is flushed into the blood with very limited
BBB penetration (Furtado et al., 2018), it is reasonable to
hypothesize that intraventricular NTF delivery is a suboptimal
delivery method for most of the NTFs in PD. In the second
phase II trial 15 µg/24 h of GDNF was continuously infused
to the putamen of the patients. The treatment was rather well
tolerated, yet showed no therapeutic benefit for the patients (Lang
et al., 2006). Importantly, the development of GDNF-neutralizing
antibodies in six patients argues for the peripheral leakage of
GDNF, suggesting problems with the mini-pump connection
and uncertainties in the amounts of GDNF delivered into the
brain. In the third double-blind phase II clinical study in PD
patients intraputamenal CED of GDNF protein was used, where
GDNF was delivered once a month to the putamen at a dose of
120 µg per putamen. Again, the motor UPDRS scores did not
significantly differ between the GDNF and the placebo groups,
albeit significant improvements were observed in individual
cases. It was suggested that intermittent intraputamenal CED of
GDNF resulted in an adequate coverage of the putamen with
NTF, overcoming prior drug delivery limitations (Whone et al.,
2019). Moreover, since GDNF binds readily to the cell surface
and extracellular matrix heparin sulfate proteoglycans (Bespalov
et al., 2011) and diffuses poorly in the brain, it was suggested
that 120 µg per putamen per month was perhaps not enough to
induce a significant effect. The coverage of GDNF delivered to the
putamen utilizing CED is around 30% (transfrontal approach) or
50% (posterior approach) (Barker et al., 2020). For comparison,
the coverage of the putamen in the CDNF Phase I trial was
predicted to be around 60–75% using similar device and delivery
site (e.g., infusion into putamen using CED). Thus, it is expected
that bioavailability of CDNF to the neuronal axons is significantly
higher compared to GDNF due to its better diffusion properties
(Voutilainen et al., 2011).
NTF Dosage and Continuity of the
Infusion–Continuous vs. Intermittent
There is still a debate regarding the NTF doses and continuity of
infusion to achieve the best results. The majority of clinical trials
in PD patients have been conducted using continuous infusion
of high doses of NTFs or their constitutive overexpression
from viral vectors. However, by characterizing the distribution,
toxicity and the functional effects of GDNF after CED into the
striatum of rats in vivo, Taylor et al. (2013) concluded that high
concentrations (above 0.6 µg/µl) of GDNF were associated with
neuronal and synaptic toxicity. This study advised that “CED of
low concentrations of GDNF, with dosing intervals determined
by tissue clearance, has most potential for effective clinical
translation by optimizing distribution and minimizing the risk
of toxic accumulation.” Interestingly, the preliminary report on
phase I-II clinical study of CDNF in PD patients also suggested
that the improvement of the DAT PET was mostly characteristic
for the mid-dose CDNF patients (120 µg for 3 months + 400 µg
for 3 months) compared to the high-dose patients (120 µg for
2 months + 400 µg for 2 months + 1200 µg for 2 months)
(Herantis Pharma, 2020). Considering that cellular responses to
the NTFs can be bell-shaped [e.g., effect of the GDNF on the
neurite outgrowth is higher in case of lower doses (Mills et al.,
2007)], it is crucial to optimize the dose of each NTF in clinical
trials individually, depending on the delivery method as well as
the physico-chemical and biological characteristics of the NTF.
Patient Age and Stage of the Disease
When PD is first diagnosed, there is around 50–70% reduction
in the density of axons of dopamine neurons in the putamen
and about 30% reduction in the number of cell bodies in the
SNpc (Cheng et al., 2010). By 5–6 years post-diagnosis, the
putamen is nearly completely devoid of the axons of dopamine
neurons, leaving only a small number of neuronal axons that
can be restored by potential treatments (Kordower et al., 2013).
Currently, only middle- to late-stage (mainly >8 years post-
diagnosis) PD patients are eligble for the intracranial treatment
with NTFs, meaning there are almost no axons to restore in the
putamen. In the ideal case, the treatment of PD patients should
be started as soon as the diagnosis is clear and confirmed (some
time windows are advised to follow the PD progression, since
there are curently no 100% reliable methods for early diagnosis),
and this is ethically acceptable only in case peripheral delivery.
Development of novel (targeted) delivery systems would help to
overcome this problem and allow treatment of PD patients with
NTFs immediately after the diagnosis.
Solving the Delivery Problem: From
Intracranial Delivery to Nanoparticles
and Brain Targeting
Particle-based delivery systems are of considerable interest
because particles can improve the solubility of NTFs, prolong
the half-life of NTFs in blood circulation and/or in the brain,
provide a controlled sustained release of NTFs and improve
the local delivery of NTFs or enable the delivery in a systemic
manner (Tan et al., 2012). For PD therapy, particles can be
delivered to the brain by at least three different routes: locally,
systemically or intranasally, and by the means of differently
sized particles: microparticles or NPs (Torres-Ortega et al., 2019).
Early proof of concept studies on NTF delivery with particles
focused mainly on microparticles and local administration via
stereotactic surgery (Jollivet et al., 2004; Clavreul et al., 2006;
Tatard et al., 2007; Garbayo et al., 2011, 2016; Herrán et al., 2013,
2014; Requejo et al., 2015). As an important milestone, the safety
and efficiency of GDNF encapsulated into microparticles was
demonstrated in the experiments with parkinsonian monkeys.
In this study micro-encapsulated GDNF injected into putamen
provided motor improvement and dopaminergic function
restoration in monkeys lesioned by 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) (Garbayo et al., 2016). In another set
of studies, superior restorative effect of the combination of GDNF
and vascular endothelial growth factor (VEGF) encapsulated into
micro- or nanospheres and implanted into 6-OHDA-lesioned
rats was demonstrated (Herrán et al., 2013, 2014).
Increasingly, the local delivery by microparticles was replaced
by systemic delivery using particles with at least one size
dimension below 100 nm, e.g., NPs. Similarly to microparticles,
NPs improve the pharmacokinetic properties of NTFs, and due to
their small size they also facilitate the delivery of NTFs through
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the BBB. NPs or other nanoscale structures that are a part of drug
formulations, are referred to as nanomedicines. Box 2 defines the
use of terms “NPs” and “nanomedicines” in the current review.
Within the realm of nanomedicine, NPs are often used
as non-viral vectors for drug delivery to different cells and
organs, including the brain. Depending on the properties of
the drugs, they can be either placed into NPs or attached to
their surfaces. The first NPs for drug delivery were developed
in the 1960s (Kreuter, 2007). Despite the relatively long history
of nanomedicine, however, there were only 56 U.S. Food and
Drug Administration (FDA)-approved nanomedicines on the
market in 2016 (Bobo et al., 2016) and around 30 nanomedicines
approved by the European Medicines Agency (EMA) in 2018
(Soares et al., 2018). However, the number of approved medicines
is growing rapidly, and more than dozen of nanomedicines are
currently in clinical trials (Gadekar et al., 2021). Remarkably,
one of the last approved nanomedicines are lipid-based NPs
that are now a key component of COVID-19 mRNA-based
vaccines, BioNTech/Pfizer’s BNT162b2 and Moderna’s mRNA-
1273 (Shin et al., 2020; Nature Reviews Material Editorial, 2021),
demonstrating increasing importance of nanomedicines.
Most of the approved nanomedicines are anti-cancer drugs,
whereas the main benefit of “nano” is in the improvement of
the physico-chemical properties and stability of the active drug
and its passive accumulation in tumor cells, while the active
cell- and organ-targeting has not been achived yet, despite some
encouraging data from animal models. In the highly cited and
discussed article, after analyzing the scientific literature from
the past 10 years, Wilhelm et al. (2016) concluded that “only
around 0.7% (median) of the administered NP dose is found
to be delivered to a solid tumor.” This problem is more than
relevant for the brain targeting by NPs, since brain is the most
poorly accessible organ in the body due to the presence of the
BBB that protects the brain from harmful environmental factors,
chemicals and drugs.
To the best of our knowledge, there are no FDA-approved
nanomedicines on the market yet that facilitate the penetration
of drugs through the BBB. However, there are numerous research
articles demonstrating that drugs that do not cross the BBB can
be loaded into NPs and transported into the brain in vivo (Saraiva
et al., 2016). In the current review, we focus on NP-mediated
delivery to the brain, although many alternative non-invasive
strategies are being actively explored to tackle or surmount
the BBB, including several relatively new approaches such as
transient opening of the BBB by ultrasound, laser light or
BOX 2 | Definitions of nanoparticles and nanomedicines.
Nanoparticles: Natural, incidental or manufactured particles with three
external dimensions at “nanoscale,” i.e., in the size range of 1–100 nm
(ISO/TS 80004-2:2015). In the current review we mean manufactured
(synthetic) nanoparticles.
Nanomedicine: “A branch of medicine that applies the knowledge and tools
of nanotechnology to the prevention and treatment of disease. Nanomedicine
involves the use of nanoscale materials /. . . / for diagnosis, delivery, sensing or
actuation purposes in a living organism” (Nature, 2020). Colloquially, the plural
form “nanomedicines” usually refers to the products of nanomedicine.
chemicals, intranasal delivery, or facial intradermal injections
(Khan et al., 2017; Furtado et al., 2018). Due to the small size
and large surface area, NPs display advantages as drug delivery
systems, posing high drug loading capacity and penetration of
biological barriers. As exemplified below, in some cases NP-
mediated delivery can be combined with alternative approaches,
such as transient opening of the BBB and intranasal delivery. In
addition, NPs can be functionalized with brain-targeting ligands
to reinforce their BBB penetration.
The BBB consists of tightly connected monolayer of brain
endothelial cells sheathed by astrocyte end-feet (Figure 3) that
is impermeable to almost 100% of large molecules and about
95% small molecules. The BBB acts as a physical barrier due to
the presence of intramembranous proteins called tight junctions
that connect endothelial cells and form a highly selective network
to force most molecular traffic toward a transcellular route
(i.e., through cells) across the BBB, rather than the paracellular
route (i.e., through the intercellular space between cells), as
in most endothelia (Abbott et al., 2006). BBB permeability is
actively regulated by the cross-talk between endothelial cells,
astrocytes and several other cell types (microglia, pericytes,
oligodendrocytes, neurons etc.) that localize on the “brain”
side and, altogether, form a functional structure known as the
neurovascular unit (Furtado et al., 2018).
The composition, characteristics, permeability regulation of
the BBB and their considerations for NP-mediated delivery have
recently been described in an excellent review by Furtado et al.
(2018). Proteins such as NTFs are transported through the BBB
via receptor-mediated transcytosis (Sweeney et al., 2018), e.g.,
they are taken up by endocytosis of endothelial cells on the
“blood” side and released to the “brain” side. The surface of the
capillary basement membrane is almost completely covered by
FIGURE 3 | Schematic structure of the blood–brain barrier. Modified from
Abbott et al. (2006) and Lau et al. (2013). Neurotrophic factors and
nanoparticles are mainly transported through the BBB via receptor-mediated
transcytosis or endocytosis. Once across the BBB, NTFs, and NPs must
traverse the extracellular space (ca 40 nm microenvironment formed by gaps
between brain cells) that limits the diffusion of molecules that are significantly
larger than 40 nm or/and bind to the extracellular matrix. It has been
suggested that NPs may also follow the alternative, “speedy cytoplasmic
route” through the brain tissue, assumingly via the connections of astrocytes
(Kreuter, 2014).
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the end-feet of astrocytes that are separated from the capillary
endothelium by a distance of only 20 nm (Sonavane et al.,
2008). Thus, to reach the brain, the molecules, NTFs of NPs
should be transported across the membranes of several cell
types, i.e., endothelial cells and astrocytes. Once across the BBB,
molecules or NPs must traverse extracellular space (narrow
microenvironment formed by gaps between brain cells) that
is around 40 nm and is partly filled by the dense negatively
charged extracellular matrix (Nicholson and Hrabìtová, 2017).
Extracellular matrix limits the diffusion of the molecules that
bind to the extracellular matrix (such as GDNF, NRTN) and
the transportation of NPs significantly bigger than 40 nm due
to size limitations. However, it has been suggested that once in
the brain, NPs may follow the speedy cytoplasmic route through
brain tissue, whereas astrocytes may provide such a cytoplasmic
route (Kreuter, 2014).
As a rule, only a tiny fraction of NTFs introduced by peripheral
delivery methods reaches the brain, since NTFs are rapidly
inactivated by cellular and extracellular proteases, excreted by
kidneys and bound by proteins and other components of the
blood and tissues (Thorne and Frey, 2001). When placed inside
or attached to the NPs, NTFs are stabilized from enzymatic
clearance and sequestration. The efficiency of NPs in delivering
the drug to the brain mainly depends on the circulation times of
NPs in the blood and the ability to cross the BBB that are largely
defined by the NP size, composition and, especially, surface
functional groups.
Nanoparticle Size
In vitro studies conducted with different cell lines and various
types of NPs have suggested that the most optimal cell association
and endocytotic uptake occur in the NP size range of 15–70 nm
(Jiang et al., 2008; Furtado et al., 2018). In general, while >100 nm
NPs are less efficient in the BBB penetration, <5 nm NPs are
quickly removed from systemic circulation by renal clearance and
will not reach brain in sufficient quantities. Shilo et al. (2015)
studied the uptake of 20, 50, 70, and 110 nm gold (Au) NPs to
mouse immortalized brain endothelial cell line bEnd3 in vitro
and showed that the 70 nm Au NPs were the most optimal for
uptake while the 20 nm Au NPs possessed the maximum free
surface area for uptake by bEnd3 cells. In another study, Ohta
et al. (2020) investigated the penetration of 3, 15, and 120 nm Au
NPs through the monolayer of bEnd3 cells in vitro, treated shortly
by focused ultrasound to induce transient widening of their tight
junctions. In this experiment, the 15 nm Au NPs showed the
highest passage through the cell monolayer. However, in vitro
studies do not provide information on the fate of NPs inside
the brain, e.g., their distribution among the brain regions, cell
population and clearance mechanisms. Sonavane et al. (2008)
studied the tissue distribution of 15, 50, 100, and 200 nm Au
NPs after i.v. administration in mice, and found that the 50 nm
and especially the 15 nm NPs were the most widespread in all
organs, including the brain. The NP percent in brain compared
to the delivered dose was low for all NPs: 0.075% for the 15 nm,
0.036% for the 50 nm, 0.023% for the 100 nm, and 0.0003% for the
200 nm NPs, demonstrating that smaller NPs should be preferred
for the brain delivery. More well-designed in vitro transcytosis
studies, and especially relevant in vivo studies are crucially needed
to understand NP size-dependent BBB penetration and the later
fate of NPs in the brain.
Nanoparticle Composition
There are many classes of NPs and a few dozen of them are
already on the market as a part of various nanomedicines (Bobo
et al., 2016). Below we briefly highlight the NP classes that
we consider the most promising for the NTF delivery to the
brain (Figure 4).
Lipid-based NPs are liposomes and solid lipid NPs. Liposomes
are among the simplest and most commonly used biodegradable
NPs enabling the delivery of the drugs through the BBB
(Torchilin, 2005; Wohlfart et al., 2012). They consist of a lipid
bilayer(s) that form a hydrophilic core. Due to this amphiphilic
structure, liposomes are able to incorporate both hydrophilic
and hydrophobic drugs. Hydrophilic drugs may be entrapped
inside the hydrophilic core of the liposomes and hydrophobic
drugs may be placed into the internal hydrophobic part of the
lipid bilayer(s). Solid lipid NPs possess a solid hydrophobic
core consisting of biocompatible lipids such as fatty acids,
waxes or triglycerides stabilized by surfactants. These NPs are
biocompatible, possess high drug entrapment efficiency, stability
and controlled release (Furtado et al., 2018).
Polymeric NPs are dendrimers, nanocapsules, or nanospheres
consisting of synthetic or natural polymers. Some of the
most widely employed polymers are poly-n-butyl cyanoacrylate
(PBCA), poly(lactic-co-glycolic acid) (PLGA), poly(glycolic acid)
(PGA), poly(L-glutamic acid) (PLE), poly(lactic acid) (PLA),
human serum albumin, and chitosan. One of the first polymeric
NPs for NTF delivery to the brain was PBCA NPs, which have
been increasingly replaced by biodegradable PLA, PLE, or PLGA
NPs. PLGA NPs have been approved by FDA and EMA for use in
drug delivery systems (Kurakhmaeva et al., 2009; Danhier et al.,
2012).
Dendrimers, such as polyamidoamine dendrimers
(PAMAMs), have been successfully used for the delivery of
NTF genes. Under physiological conditions, PAMAM-DNA
complexes have a positive net charge that facilitates their
interaction with net negatively charged cell membrane.
Inorganic non-degradable NPs such as fullerenes, metal-
based NPs and carbon-based nanomaterials have a lower clinical
potential compared to biodegradable NPs. However, inorganic
NPs are frequently used as tools in the proof-of-concept studies,
since they are often easily detectable in cells by analytical
methods: inductively coupled plasma mass spectrometry for
the detection of metals, measurement of surface plasmon
resonance characteristics for Au and Ag NPs, and fluorescence
characteristics for graphene quantum dots, etc. In addition,
several exciting articles have recently demonstrated that some
inorganic NPs such as Au and graphene quantum dots efficiently
penetrated the BBB and per se prevented and reversed alpha-
synuclein (αSyn) aggregation in a PD model [graphene quantum
dots (Kim et al., 2018)], and inhibited amyloid beta (Aβ)-
related toxicity in AD models [Au NPs (Javed et al., 2019)] and
carbon dots (Zhou et al., 2019). In the section “Perspective”
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FIGURE 4 | Schematic illustration of various classes of NPs suitable for the delivery of NTFs through the blood–brain barrier.
of this review, we discuss in more detail potential therapeutic
impact of these NPs.
Neurotrophic factors are encapsulated into NPs or attached to
their surface using different methods, depending on the physico-
chemical properties of NPs and NTF (Figure 5). NTFs or genes
of NTFs may be incapsuated into PAMAMs or loaded into
liposomes as described for BDNF and GDNF genes (Xing et al.,
2016; Lin et al., 2020). In case of polymeric as well inorganic NPs,
NTFs can be conjugated via surface groups or adsorbed passively
onto the surface on NPs (this study, Figure 6). Finally, NTFs
can be attached to the polymers of polymer-polyethylene glycol
(PEG) complexes to form self-assembilng NPs (Jiang et al., 2018).
FIGURE 5 | Schematic illustration of the mechanisms of NTFs’ (green dots)
binding to NPs.
Nanoparticle Surface Modifications (Coatings)
Nanoparticle surface modifications include molecules, polymers
or peptides covalently or non-covalently attached to the NPs.
These surface ligands are crucial for improved delivery of NPs to
the brain, since they either prolong the circulation of NPs in the
blood or facilitate the penetration of NPs through the BBB, mostly
via the interaction of NP-attached ligand with the receptors on
brain endothelial cells.
Surface functionalizations prolong NP circulation in the
blood
The first type of surface functionalization has been applied
to “stealth” NPs–e.g., to increase their circulation rates in
the bloodstream by protecting them from the adsorption of
blood proteins that promote NP uptake by the cells of the
reticuloendothelial system (Ke et al., 2017). In addition, blood
proteins and other molecules that non-specifically adsorb onto
the surface of NPs in biological fluids (e.g., blood) may reduce the
efficiency of targeting ligands by physically masking the latter’s
action (Monopoli et al., 2012). To prevent the adsorption of
proteins, NP clearance by immune cells, and masking of targeting
ligands, NPs are often functionalized with PEG or dextran. This
is one of the oldest strategies for improving the circulation rates
of NPs and individual drugs. In addition, dense coating of NPs
with PEG improves their diffusion in the brain, even for NPs
of >100 nm in size, whose limited diffusion inside the brain is
otherwise minimal (Nance et al., 2012).
Non-covalent surface modifications improving BBB targeting
The second type of NP surface modification was described
decades ago, which relies on the application of different
surfactants such as polysorbate 80 or poloxamer 188 (PX188)
that guide NPs to the brain (Gulyaev et al., 1999). The precise
mechanism of surfactant-NP-mediated uptake through the BBB
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is still under debate, from increasing the adsorption of NPs
to blood capillaries and increased retention until inhibition of
the efflux system, especially by P-glycoprotein (Kreuter, 2014).
One of the prevailing explanations suggests that polysorbate
80, PX188 and some other surfactants facilitate the adsorption
of apolipoproteins E or A–I from blood that trigger the
interaction of surfactant-coated NPs with receptors on brain
endothelial cells, thereby enabling NPs to cross the BBB via
endocytosis (Kreuter et al., 1997; Saraiva et al., 2016). In our
study, we employed this strategy to deliver peripherally injected
radioactively labeled CDNF through the BBB (Figure 6, our
unpublished preliminary data). For that we adsorbed 125I-labeled
CDNF to the non-toxic biodegradable PLGA NPs (200 nm,
Phosphorex) and overcoated the construct with PX188 to
enhance their brain targeting. We demonstrated that a 1.5-fold
more radioactivity (expressed as counts per minute, CPM) was
detected in the brain of rats in terms of the CDNF adsorbed to
NPs (125I-CDNF-NP) compared to free non NP adsorbed CDNF
(125I-CDNF) 1 h after subcutaneous injection. In addition to the
radioactivity in the brain, we also measured radioactivity values
in other organs as a proxy for CDNF distribution. We observed
that: (1) the fraction of CDNF was negligible in the brain (0.03%
without NPs and 0.046% with NPs) compared to other organs,
and (2) in most organs, their radioactivity levels were increased
in terms of CDNF-NP compared to free CDNF (Figure 6B).
This suggests that the effect of NPs was not brain-specific: NPs
rather increased the stability of CDNF, leading to increased levels
of CDNF in different organs including the brain. To specifically
target the brain, novel mode advanced methods are needed, and
some approaches are discussed below.
Covalent surface modifications improving BBB targeting
The third and the most “modern” approach relies on the
surface functionalization of NPs with BBB targeting ligands such
as transferrin, insulin, lactoferrin, apolipoproteins, antibodies,
cell penetrating peptides, or homing peptides. These ligands
are either recognized by the respective receptors on brain
endothelial cells, endocytosed by endothelial cells and released
on the “brain side” of the BBB (transferrin, insulin, lactoferrin,
apolipoproteins, antibodies, and many homing peptides), or
penetrate directly through cellular membranes (cell-penetrating
peptides) (Sullivan and Toulouse, 2011; Niewoehner et al., 2014).
Some representative examples of targeting ligands used for the
transportation of NTFs through the BBB or bypassing the BBB
are shown in Table 2. One of the pioneering works in this
field was published by Wu and Pardridge (1999). The authors
conjugated BDNF to the transferrin receptor antibody OX26 and
demonstrated restoration of CA1 region in hippocampus after
ischemia in rats after i.v. delivery of PEG-BDNF-OX26. Later,
transferrin and lactoferrin were attached to different types of
nanocarriers and used to deliver various NTFs across the BBB
(Table 2). However, this method provided only about a 2 to
3-fold improved transport across the BBB (Xing et al., 2016).
PAMAMs functionalized with lactoferrin and PEG were used
to deliver the GDNF gene in a 6-OHDA rat model. Since both
lactoferrin and transferrin are large proteins (over 70 kDa),
subsequent attempts were made to reduce the length of these
targeting ligands to improve the efficiency of delivery. For
example, Prades et al. (2012) conjugated short homing peptide
THRPPMWSPVWP (THR) targeting the transferrin receptor
to Au NPs, together with the therapeutic peptide CLPFFD to
destroy the toxic aggregates of β-amyloid in AD. The authors
showed that the concentration of Au NPs in rats was about 3–
4 times higher than Au NPs without THR after 1 h i. p. injection.
Still, the percentage of THR-CLPFFD-Au NPs was low in the
brain: 0.0765% from injected dose in the best case, at 2 h after
i. p. injection. Since it was previously demonstrated that short
peptides called angiopeps exhibited a higher transcytosis capacity
and parenchymal accumulation in an artificial in vitro BBB model
than transferrin and lactoferrin (Demeule et al., 2008), angiopep-
and PEG-conjugated dendrigraft poly-L-lysine NPs were used
to transport GDNF gene through the BBB (Huang et al., 2013).
Rotenone-treated rats with five injections of angiopep-PEG-
dendrigraft poly-L-lysine NPs bearing GDNF gene demonstrated
the best improved locomotor activity and an apparent recovery of
dopamine neurons compared to the control and groups receiving
lower doses of angiopep-PEG-dendrigraft poly-L-lysine NPs. The
exact percentage of NPs reaching the brain was not determined
in this study. However, the body distribution of 125I-labeled
angiopep-conjugated NPs was studied by Ke et al. (2009) in
murine brains 48 h after i.v. injection of NPs with different ratios
of angiopep. This study demonstrated that the concentrations
of 125I-labeled angiopep-conjugated NPs with different ratios of
angiopep were 3.06, 5.12, and 8.42-fold higher in the brain than
NPs without angiopep, where the increasing rate of brain uptake
corresponded to the higher ratio of angiopep in NPs. Thus,
short peptides seem to be a promising approach to increase NP
delivery to the brain, and the research and development of new
brain-targeting peptides or optimization of old ones may be a
valuable strategy.
Alternative Strategies: Bypassing the BBB or BBB
Opening
As the delivery of NTFs to the brain using NPs functionalized
with the BBB-targeting ligands did not lead to major
breakthroughs just yet, various alternative strategies were applied
to bypass or transiently open the BBB. In the relatively modern
non-invasive delivery method relying on transient opening of
the BBB, the surface of NPs can be functionalized with, e.g.,
microbubbles (MBs) that oscillate during the application of
ultrasound, leading to transient opening of the BBB. Recently,
MBs-functionalized liposomes with GDNF or/and BDNF genes
were successfully delivered through the BBB in vivo in mice after
i.v. administration and subsequent ultrasound-assisted transient
BBB opening. Both GDNF and BDNF provided a neuroprotective
effect in a mouse MPTP model of PD, with improvements shown
in behavioral deficits and rescued dopamine neurons (Lin et al.,
2016, 2020).
An alternative non-invasive delivery method bypassing the
BBB is intranasal delivery (Aly and Waszczak, 2015) that can be
combined with the targeted delivery. For example in the study
by Hernando et al. (2018), human immunodeficiency virus 1
(HIV-1)-derived cell-penetrating transactivator of transcription
(TAT) peptide was conjugated to chitosan-lipid NPs bearing
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FIGURE 6 | Delivery of 125 I-labeled CDNF through the blood–brain barrier in vivo using nanoparticles [counts per minute (CPM) per mg tissue]. 125 I CDNF was
adsorbed on the surface of 200 nm poly(lactic-co-glycolic acid) nanoparticles (125 I CDNF-NP) or used without NPs (125 I CDNF) and administered subcutaneously
in vivo in rats (100 µl equaling to 954 000 CPM were delivered). Rats were perfused with PBS for 20 min. (A) 125 I CDNF in the brain after 1 h (CPM/mg brain).
(B) Distribution of CDNF in different organs after 1 h (CPM per mg tissue).∗p < 0.05, n = 4. Unpublished data. Experiments were performed under the permits
ESAVI/12830/2020.
GDNF and was tested in a mouse MPTP model of PD. The
TAT-NP-GDNF-treated group revealed motor recovery, which
was confirmed with immunohistochemistry studies showing
increased number of dopamine neurons in the striatum as
revealed by staining of tyrosine hydroxylase (TH), a marker of
dopamine fibers and neurons.
An interesting intranasal delivery system was recently
proposed by Jiang et al. (2018). The authors synthesized self-
assembling PEG-PLE-BDNF NPs, in which active BDNF was
released upon interaction with its receptors, minimizing potential
side effects of BDNF caused by non-specific release. The
authors administered NPs intranasally, and after 30 min detected
an increased level of nano-BDNF accumulation in the brain
(compared to native BDNF) in all studied brain regions, except
for the midbrain, where was a trend for the increased native
BDNF. The highest increase in BDNF levels was observed in
the olfactory bulb (∼6.7 times), hippocampus (∼9.9 times), and
brainstem (∼4.0 times) over native BDNF. Notably, in contrast to
free BDNF, PEG-PLE-BDNF NPs significantly reduced dopamine
neuron loss in the ipsilateral SN induced by intrastriatal injection
of lipopolysaccharides.
One of the latest non-invasive delivery methods bypassing
the BBB is a newly discovered methodology utilizing the
brain lymphatic vasculature. Recent proof-of-concept study
demonstrated that this method, which relies on subcutaneous
injection of NPs at the neck near the lymph node, is 44-fold more
efficient compared to conventional i.v. route for fluorescent-dye
loaded PLGA NPs in mice (Zhao et al., 2020). To the best of our
knowledge, this method has not yet been used for the delivery of
NTFs through the BBB.
Summary: The Potential of Nanoparticles
for Improved NTF Delivery to the Brain
The NP-mediated delivery of NTFs to the brain is a complex
phenomenon and its efficiency is a sum of several components:
(a) stability of NTFs in the body fluids, (b) ability of NTFs to
penetrate the BBB, and (c) diffusion of NTFs in the brain and
their bioavailability to the target cells. Very few studies have so far
addressed all of these components and mostly have reported the
final result: improved locomotor behavior, reduced loss of TH+
neurons in the SN or the fold increase of NTF-NP concentration
in the brain compared to the free NTFs. Below we elaborate
on different components of successful NP-mediated delivery of
NTFs to the brain and briefly summarize what may be achieved
by the means of NPs.
Clearly, NPs can improve the stability of NTFs in the
body fluids. While free NTFs are easily removed from
circulation due to their rapid degradation by extracellular
peptidases, tissue binding, receptor-mediated clearance, and
glomerular filtration (Thorne and Frey, 2001), placement
of NTFs into or onto NPs protects NTFs from enzymatic
cleavage and tissue binding (physical protection) as well as
glomerular filtration (glomerular filtration efficiently removes
1–30 kDa-sized peptides and proteins, while NPs increase
their size). Conjugation of PEG to NTFs and NPs may
further improve their pharmacokinetic properties and stability
(Milton Harris and Chess, 2003).
Can NPs significantly improve the transportation of NTFs
across the BBB? Although the types of NPs, time points,
endpoints, animal models, and NP delivery methods are different
in various studies and therefore cannot be compared in a
straightforward manner, we have extracted relevant numbers
from different articles to derive a sketch about the efficiency of
current targeted systemic deliveries. Modest increases in NTF
delivery by NPs were reported using large targeting ligands
[transferrin: 2–3 times higher immunoreactivity of BDNF in
cerebral cortex of rats compared to the background in naïve
rats (Xing et al., 2016)] and surfactants (PX188): 1.5-fold
higher radioactivity of 125I-CDNF-NP in the brain of naive rats
compared to free 125I-CDNF (this study, Figure 6A). Promising
results were reported by using the high ratio of short peptide
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TABLE 2 | Ligands used for nanoparticles, for the transportation of neurotrophic factors through the blood–brain barrier.
Strategy Ligand Example Effect; administration route* References
Targeting of transferrin
receptor
TfR antibody (OX26) PEG-BDNF-OX26 Restoration of CA1 region in hippocampus after ischemia in








Increased immunoreactivity of BDNF in cerebral cortex of







Dose-dependent improvement in locomotor activity and






Angiopep (19 aa) Dendrigraft
poly-L-Lys-PEG-GDNF
gene-angiopep
Improved locomotor activity and recovery of dopamine
neurons in rotenone rat PD model
Huang et al.,
2013
Conjugation of NTF to
cell penetrating peptide
(CPP)
TAT (11 aa) TAT-GDNF Increased number of viable neurons in the striatum after
ischemia; i.v.
Kilic et al., 2003
Conjugation of NTF to
CPP
TAT TAT-GDNF TAT-GDNF fusion protein reached dopamine neurons but




Bypassing of BBB None PEG-PLE-BDNF NPs Active BDNF was released upon interaction with its
receptors, minimizing potential side effects. Increased level
of BDNF-containing NPs accumulated in the brain
(compared to native BDNF) in all studied brain regions,




Conjugation of NTF to
CPP
TAT Chitosan-TAT-GDNF Increased number of viable TH+ neurons, decreased
















Improvement of behavioral deficits and rescued dopamine
neuron loss in MPTP mice in GDNF, BDNF and
GDNF+BDNF groups; i.v.











Localized delivery of GDNF to striatum; 11-fold increase in
striatal GDNF in 6-OHDA-treated rats. 2.2-fold increase in
DA levels, 3.2-fold increase in dopamine cell number in the
SNpc and 5-fold increase in TH+ fiber density in the
striatum at week 12 in 6-OHDA-treated rats. i.v.
Mead et al.,
2017
* i.n. – intranasal delivery, i.v. – intravenous delivery.
angiopep conjugated to NPs: 3.06, 5.12 and 8.42-fold higher 125I-
angiopep-NP radioactivity in the brains of mice compared to NPs
without angiopep (Ke et al., 2009). The most promising results
were reported for transient opening of the BBB, where an 11-fold
increase in striatal GDNF protein was achieved in 6-OHDA-
treated rats (Mead et al., 2017). Notably, the NP percentage in the
brain compared to the delivered doses were still remarkably low
in all identified studies and varied from 0.01 to 0.077%, whereas
most of the NPs were localized in the spleen or liver (Sonavane
et al., 2008; Prades et al., 2012; Rich et al., 2020; this study,
Figure 6B). Thus, the efficiency of NPs in the transportation of
NTFs across the BBB is still far from optimal.
Can nanoparticles facilitate spreading of NTFs inside the
brain? The diffusion of free NTFs in the brain depends on the
NTF size, charge, and presence of NTF receptors. The diffusion
of smaller (<10 kDa) NTFs is not significantly restricted, while
larger NTFs (>40 kDa) whose sizes begin to resemble the
dimensions of extracellular space (15–40 nm), may encounter
diffusion restrictions (Nicholson and Tao, 1993; Thorne and
Frey, 2001). In addition, the presence of high-affinity receptors
at NTF delivery sites may hinder the diffusion of NTFs. For
example, Yan et al. (1994) injected radioactively labeled NGF,
BDNF, and neurotrophin-3 (NT-3) into rat lateral cerebral
ventricle and followed their distribution in the brain. While NGF
reached the target cells, injection of BDNF resulted in few or
no labeled neurons in the basal forebrain or in the SN. The
authors concluded that the abundant expression of the BDNF
receptor, TrkB, on the ependymal layer of the ventricle and brain
parenchyma was the main reason behind the poor access of
BDNF to its cellular targets.
Nanoparticles may help to overcome these difficulties. While
NTFs diffuse in the extracellular space, NPs may follow the speedy
cytoplasmic route through brain tissue. Since it is known that
astrocytes make cytoplasmic bridges between different brain cells
and connect a wide range of brain regions, it was suggested that
astrocytes offer a “network of highways” that can be used by
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polymeric NPs to move inside the brain cells (Kreuter, 2014).
PEGylation of NPs seems to facilitate the spreading of NPs inside
the brain. It has been demonstrated in vivo and ex vivo in brain
tissues that PEG-functionalized PLGA NPs diffuse in normal
rat brain and PLGA NPs without PEG functionalization do not,
whereas the percent of diffusive fractions correlated with the PEG
surface density and NP size (Nance et al., 2012). Thus, PEGylated
NPs might help to facilitate the diffusion of NTFs inside the brain
that is especially useful for the NTFs such as GDNF that are
readily bound by the components of extracellular matrix.
Nanoparticles can also mitigate other possible risks associated
with the systemic delivery of NTFs, for example, possible side
effects such as immune response or activation of receptors in
“wrong” tissues. An intracerebroventricularly delivered GDNF
trial was halted due to side effects (Nutt et al., 2003), which were
likely due to extremely high GDNF doses affecting hypothalamus.
Considering that GDNF receptors are expressed in different
organs throughout the body, Manfredsson et al. (2020) suggested
that GDNF administration for PD likely requires site-specific
putaminal delivery that seems to be more advantageous over
systemic delivery. However, targeted delivery with NPs would
allow systemic treatment with NTFs by increasing the doses of
NTFs in the brain and decreasing it, in the periphery. Since
in PD dopamine neurons degenerate not only in the SN, but
also in other brain regions, as well as in the periphery, it would
be beneficial for NTFs to reach these neurons. In addition, in
contrast to GDNF, CDNF, and MANF act mostly on stressed and
diseased neurons and, therefore, their presence in the periphery
could be beneficial for, e.g., enteric neurons (Lindahl et al., 2020)
to relief the non-motor symptoms of PD such as constipation.
Despite initial encouraging results on safety of some NPs
and their approval by FDA and EMA, potential side effects
of NPs in the context of neurodegenerative diseases should be
thoroughly explored. As stated in the recent review, no single
clinical trial based on the use of NPs to treat PD has been
registered yet (Torres-Ortega et al., 2019). Authors concluded
that the scarcity of validated methods for characterization of
NPs, manufacturing issues and safety and clinical translation
concerns are main current limitations of nanotechnologies for
PD therapy that should be considered during development of
nanomedicines for PD.
PERSPECTIVE
Nanoparticle-Mediated Drug Delivery for
Emerging Approaches
While NTFs maintain and restore dopamine neurons that are
damaged but not lost, cell transplants are suggested to restore
the lost cells. Relatively large number of clinical transplantation
trials using developing dopamine neurons from human fetal
midbrain has been conducted. Although the outcomes were
positive in some PD patients, there were numerous problems in
other patients such as graft-induced dyskinesia or propagation of
pathological αSyn aggregates into the grafted cells (Li et al., 2008).
Recently, the first studies using human stem cell-derived and
pluripotent stem cell-derived dopamine neurons were conducted
(Barker et al., 2018; Schweitzer et al., 2020; Tao et al., 2021). A key
requirement for cell-replacement therapy to be successful is that
engrafted neurons stay alive and integrate into resident neuronal
networks by forming new synaptic contacts (Parmar et al., 2020).
NTFs delivered systemically with NPs could serve as a supporting
tool in these therapies, keeping neurons alive and facilitating the
establishment of neuronal contacts (Gantner et al., 2020).
Another PD therapy is the use of small molecules that
mimic the action of NTFs, NTF mimetics, e.g., GDNF
family ligands (GFLs) that promote the survival of different
neuronal populations. Despite their promising neurorestorative
properties, these molecules still suffer from poor pharmacological
characteristics, do not efficiently penetrate the BBB, and activate
several receptors in different cell types (Sidorova and Saarma,
2020). NPs could improve the physico-chemical properties (such
as solubility) and BBB penetration properties of these molecules.
A modern potential treatment for PD is reprogramming of
brain cells, such as in vivo conversion of astrocytes into dopamine
neurons that currently relies on genes of transcription factors
that are delivered into the brain using lentiviruses injected
into the striatum (Rivetti Di Val Cervo et al., 2017). Similarly,
reprogramming of glial cells into neurons using CRISPR-CasRx
has recently been demonstrated using Ptbp1 knockdown in the
striatum (Zhou et al., 2020). These modern techniques rely on the
delivery of DNA and RNA that could be delivered systemically
using NPs (Wei et al., 2020).
Dual Functionality of NPs
In addition to their nanocarrier function, NPs themselves
have been increasingly shown to support various functions
of neurons, prevent the aggregation of proteins, reduce
inflammation, and alleviate endoplasmic reticulum (ER) stress
caused by pathological processes in the brain of patients with
neurodegenerative diseases. This emerging dual strategy that
combines drug carrier and therapeutic function of NPs may be
of significance.
Nanoparticles as Neuroprotective and
Anti-Inflammatory Agents
Several research articles reported improved growth,
differentiation or survival of neuronal cells and neurons on
nanomaterials, especially on carbon-based materials such as
graphene (Convertino et al., 2020), carbon nanotubes (Shao
et al., 2018), and nanodiamonds (Alawdi et al., 2017). Some
forms of graphene oxide prevented the loss of dopamine
neurons and decreased αSyn levels in vitro in the cell line
SN4741 derived from the murine SN (Rodriguez-Losada et al.,
2020). Graphene promoted axonal elongation by reducing the
number of retrogradely transported NGF in the culture of
primary dorsal root ganglion neurons (Convertino et al., 2020).
Nanodiamonds decreased inflammation, improved learning, and
stimulated expression of BDNF in an aluminum-induced rat
model of AD, probably via modulation of the NF-κB pathway
(Alawdi et al., 2017). Similarly, several inorganic NPs were
neuroprotective against inflammation and reactive oxygen
species (ROS). For example, selenium NPs reversed oxidative
damage and neuronal loss in a mouse model of epilepsy
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(Yuan et al., 2020) and cerium oxide NPs blocked pro-
inflammatory signaling and drove microglial transformation
from a pro-inflammatory phenotype to an anti-inflammatory
phenotype under pathological conditions in microglial cell
line BV-2 (Zeng et al., 2018). Similarly, biomimetic NPs
coated with the cell membranes of neuronal cells promoted
the transformation of microglia into the anti-inflammatory
phenotype to relieve neuroinflammation and recover dopamine
levels in a mouse model of PD (Liu et al., 2020). Thus, some NPs
could serve as therapeutics by reducing ROS and inflammation
which underlie neurodegenerative diseases.
Nanoparticles as Inhibitors of Protein Aggregation
Aggregation of proteins into pathological fibrils and subsequent
ER stress caused by misfolded proteins are common hallmarks
of a range of neurodegenerative diseases including Aβ in AD
and αSyn in PD. Inhibiting protein amyloid aggregation has
become one of the popular approaches to potentially treat AD
and PD. Several articles have recently demonstrated that Au and
carbon-based NPs efficiently penetrated the BBB and, in addition
to their nanocarrier function, prevented and reversed αSyn
aggregation in PD models and Aβ aggregation in AD models.
It has been demonstrated that graphene quantum dots not
only prevented formation of αSyn fibrils but also disassembled
formed fibrils (Kim et al., 2018). Specifically, the authors of
the latter study demonstrated that the protective effects of
quantum dots were also valid in vivo in an αSyn fibrils-induced
mouse model of PD: stereotaxically injected αSyn provoked
accumulation of fibrils in the striatum and SN but systemic
administration of graphene quantum dots reduced the levels of
phosphorylated αSyn in murine brain and reduced behavioral
deficits. The mechanism of pathological fibrillar remodeling is
not fully understood but it is most probably attributed to the
reduction of β-sheets and increase of α-helices and random coils
in the secondary structure of αSyn fibrils by graphene quantum
dots. Since quantum dots contained a high number of COOH
groups on their surface, these groups could interact with the
positively charged N-terminal domain of α-Syn and facilitate
disaggregation of αSyn fibrils (Kim et al., 2018). Similar findings
have been reported for Aβ-forming fibrils and plaques in AD,
where Au NPs, graphene and carbon dots inhibited Aβ fibrillation
and remodeled previously formed fibrils (Mahmoudi et al., 2012;
Javed et al., 2019; Zhou et al., 2019), probably by clearance and
extracting peptides from Aβ fibrils (Yang et al., 2015). Javed
et al. (2019) demonstrated that Au NPs sequestered intracerebral
Aβ due to their capacity to bind with misfolded proteins in
a chaperone-like manner. All above-mentioned NPs bear a
significant potential for the treatment of protein-aggregation-
related neurodegenerative diseases via dual strategies combining
the properties of NPs as drug carriers and as drugs themselves to
mitigate protein aggregation and ER stress.
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